Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

4 clinical studies listed.

Filters:

Phase 2

Tundra lists 4 Phase 2 clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT07283731

Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma

To learn if zanzalintinib and pembrolizumab can help to control select subtypes of advanced/metastatic soft-tissue sarcoma (UPS, MFS, HGPS, and HGUS

Gender: All

Ages: 18 Years - Any

Updated: 2026-08-20

1 state

Phase 2
Zanzalintinib
Pembrolizumab
+2
NOT YET RECRUITING

NCT07610525

Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial

To learn whether certain blood and imaging tests can show which people with early-stage TNBC may already have had a complete response to chemotherapy before they go to surgery.

Gender: All

Ages: 18 Years - Any

Updated: 2026-05-28

1 state

Triple Negative Breast Cancer
Blood and Image Guided
Optimization of Neoadjuvant Therapy
+1
RECRUITING

NCT07382739

A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"

To learn if low doses of radiation therapy can help the drug elranatamab enhance the killing effect of the cancer cells.

Gender: All

Updated: 2026-04-14

1 state

Phase 2
Radiotherapy-Induced Immune Priming
Elranatamab
+4
NOT YET RECRUITING

NCT07511023

Phase 2 Trial Of Sacituzumab Tirumotecan For Treatment Of Refractory Metastatic Or Unresectable Squamous Cell Carcinoma Of The Anus/Rectum

To look at the effectiveness of sacituzumab tirumotecan (MK-2870) in treating participants with treatment-refractory unresectable and/or metastatic anal/rectal cancer.

Gender: All

Ages: 18 Years - Any

Updated: 2026-04-06

1 state

Phase 2
Sacituzumab Tirumotecan
Refractory Metastatic
+2